Alzheimer's Disease, Familial, Panel
Use
This test is appropriate for individuals with relevant clinical features or a suspected diagnosis of familial Alzheimer's disease, as well as those with a family history of Alzheimer's Disease. It helps in identifying pathogenic variants that may contribute to the disease's development, providing valuable information for disease management and family planning.
Special Instructions
Ordering requires a completed test requisition form or online order submission. Specimens must be labeled with patient information, and the testing is performed following CLIA and CAP regulations. The Exome Platform accepts a variety of specimen types, while the Genome Platform is more restricted.
Limitations
The test is limited to detecting variants within the specified genes known to be associated with familial Alzheimer's Disease. It cannot detect all possible genetic contributors to the disease, nor can it provide information about non-genetic factors. The test does not guarantee the detection of all possible CNVs and is limited by the coverage of the technology used.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided